Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis

Seminars in Cell and Developmental Biology

Volumn 24, Issue 4, 2013, Pages 287-297

  Sossey Alaoui, Khalid ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer cell invasion; Invadopodia; Invasion metastasis cascade; MicroRNAs; TNBC; WAVE3

Indexed keywords

ABELSON KINASE; ACTIN; MATRIX METALLOPROTEINASE; MICORNA 31; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN P85; TUMOR MARKER; UNCLASSIFIED DRUG; WAVE3 PROTEIN;

ACTIN FILAMENT; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL MIGRATION; CELL MOTILITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84876736072     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.10.006     Document Type: Review

References (155)

1. Suetsugu S., Takenawa T. Regulation of cortical actin networks in cell migration. International Review of Cytology 2003, 229:245-286.
2. Lee T.Y., Gotlieb A.I. Rho and basic fibroblast growth factor involvement in centrosome redistribution and actin microfilament remodeling during early endothelial wound repair. Journal of Vascular Surgery 2002, 35(June (6)):1242-1252.
3. Billadeau D.D. Cell growth and metastasis in pancreatic cancer: is Vav the Rho'd to activation?. International Journal of Gastrointestinal Cancer 2002, 31(1-3):5-13.
4. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 79(December (5)). following.
5. Sossey-Alaoui K., Su G., Malaj E., Roe B., Cowell J.K. WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma. Oncogene 2002, 21(August (38)):5967-5974.
6. Kurisu S., Takenawa T. The WASP and WAVE family proteins. Genome Biology 2009, 10(6):226.
7. Kurisu S., Takenawa T. WASP and WAVE family proteins: friends or foes in cancer invasion?. Cancer Science 2010, 101(October (10)):2093-2104.
8. Sossey-Alaoui K., Head K., Nowak N., Cowell J.K. Genomic organization and expression profile of the human and mouse WAVE gene family. Mammalian Genome 2003, 14(May (5)):314-322.
9. Takenawa T., Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. Journal of Cell Science 2001, 114(May (Pt 10)):1801-1809.
10. Devriendt K., Kim A.S., Mathijs G., Frints S.G., Schwartz M., Van Den Oord J.J., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nature Genetics 2001, 27(March (3)):313-317.
11. Miki H., Miura K., Takenawa T. N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. EMBO Journal 1996, 15(October (19)):5326-5335.
12. Miki H., Suetsugu S., Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO Journal 1998, 17(December (23)):6932-6941.
13. Suetsugu S., Miki H., Takenawa T. Identification of two human WAVE/Scar homologues as general actin regulatory molecules which associate with the Arp2/3 complex. Biochemical and Biophysical Research Communications 1999, 260(June (1)):296-302.
14. Bosticardo M., Marangoni F., Aiuti A., Villa A., Grazia R.M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009, 113(June (25)):6288-6295.
15. Snapper S.B., Takeshima F., Anton I., Liu C.H., Thomas S.M., Nguyen D., et al. N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nature Cell Biology 2001, 3(October (10)):897-904.
16. Lommel S., Benesch S., Rottner K., Franz T., Wehland J., Kuhn R. Actin pedestal formation by enteropathogenic Escherichia coli and intracellular motility of Shigella flexneri are abolished in N-WASP-defective cells. EMBO Reports 2001, 2(September (9)):850-857.
17. Dahl J.P., Wang-Dunlop J., Gonzales C., Goad M.E., Mark R.J., Kwak S.P. Characterization of the WAVE1 knock-out mouse: implications for CNS development. Journal of Neuroscience 2003, 23(April (8)):3343-3352.
18. Soderling S.H., Langeberg L.K., Soderling J.A., Davee S.M., Simerly R., Raber J., et al. Loss of WAVE-1 causes sensorimotor retardation and reduced learning and memory in mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(February (4)):1723-1728.
19. Yamazaki D., Suetsugu S., Miki H., Kataoka Y., Nishikawa S., Fujiwara T., et al. WAVE2 is required for directed cell migration and cardiovascular development. Nature 2003, 424(July (6947)):452-456.
20. Yan C., Martinez-Quiles N., Eden S., Shibata T., Takeshima F., Shinkura R., et al. WAVE2 deficiency reveals distinct roles in embryogenesis and Rac-mediated actin-based motility. EMBO Journal 2003, 22(July (14)):3602-3612.
21. Linardopoulou E.V., Parghi S.S., Friedman C., Osborn G.E., Parkhurst S.M., Trask B.J. Human subtelomeric WASH genes encode a new subclass of the WASP family. PLoS Genet 2007, 3(December (12)):e237.
22. Campellone K.G., Webb N.J., Znameroski E.A., Welch M.D. WHAMM is an Arp2/3 complex activator that binds microtubules and functions in ER to Golgi transport. Cell 2008, 134(July (1)):148-161.
23. Zuchero J.B., Coutts A.S., Quinlan M.E., Thangue N.B., Mullins R.D. p53-cofactor JMY is a multifunctional actin nucleation factor. Nature Cell Biology 2009, 11(April (4)):451-459.
24. Goode B.L., Rodal A.A., Barnes G., Drubin D.G. Activation of the Arp2/3 complex by the actin filament binding protein Abp1p. Journal of Cell Biology 2001, 153(April (3)):627-634.
25. Weed S.A., Karginov A.V., Schafer D.A., Weaver A.M., Kinley A.W., Cooper J.A., et al. Cortactin localization to sites of actin assembly in lamellipodia requires interactions with F-actin and the Arp2/3 complex. Journal of Cell Biology 2000, 151(October (1)):29-40.
26. Uruno T., Liu J., Zhang P., Fan Y., Egile C., Li R., et al. Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nature Cell Biology 2001, 3(March (3)):259-266.
27. Weaver A.M., Karginov A.V., Kinley A.W., Weed S.A., Li Y., Parsons J.T., et al. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Current Biology 2001, 11(March (5)):370-374.
28. Georgiou M., Marinari E., Burden J., Baum B. Cdc42, Par6, and aPKC regulate Arp2/3-mediated endocytosis to control local adherens junction stability. Current Biology 2008, 18(November (21)):1631-1638.
29. Rohatgi R., Ma L., Miki H., Lopez M., Kirchhausen T., Takenawa T., et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell 1999, 97(April (2)):221-231.
30. Rohatgi R., Ho H.Y., Kirschner M.W. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. Journal of Cell Biology 2000, 150(September (6)):1299-1310.
31. Millard T.H., Sharp S.J., Machesky L.M. Signalling to actin assembly via the WASP (Wiskott-Aldrich syndrome protein)-family proteins and the Arp2/3 complex. Biochemical Journal 2004, 380(May (Pt 1)):1-17.
32. Burns S., Cory G.O., Vainchenker W., Thrasher A.J. Mechanisms of WASp-mediated haematological and immunological disease. Blood 2004, August.
33. Machesky L.M., Mullins R.D., Higgs H.N., Kaiser D.A., Blanchoin L., May R.C., et al. Scar, a WASp-related protein, activates nucleation of actin filaments by the Arp2/3 complex. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(March (7)):3739-3744.
34. Mullins R.D., Heuser J.A., Pollard T.D. The interaction of Arp2/3 complex with actin: nucleation, high affinity pointed end capping, and formation of branching networks of filaments. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(May (11)):6181-6186.
35. Abdul-Manan N., Aghazadeh B., Liu G.A., Majumdar A., Ouerfelli O., Siminovitch K.A., et al. Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein. Nature 1999, 399(May (6734)):379-383.
36. Aspenstrom P., Lindberg U., Hall A. Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome. Current Biology 1996, 6(January (1)):70-75.
37. Kim A.S., Kakalis L.T., Abdul-Manan N., Liu G.A., Rosen M.K. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000, 404(March (6774)):151-158.
38. Weaver A.M., Young M.E., Lee W.L., Cooper J.A. Integration of signals to the Arp2/3 complex. Current Opinion in Cell Biology 2003, 15(February (1)):23-30.
39. Higgs H.N., Pollard T.D. Activation by Cdc42 and PIP(2) of Wiskott-Aldrich syndrome protein (WASP) stimulates actin nucleation by Arp2/3 complex. Journal of Cell Biology 2000, 150(September (6)):1311-1320.
40. Eden S., Rohatgi R., Podtelejnikov A.V., Mann M., Kirschner M.W. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature 2002, 418(August (6899)):790-793.
41. Gautreau A., Ho H.Y., Li J., Steen H., Gygi S.P., Kirschner M.W. Purification and architecture of the ubiquitous Wave complex. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(March (13)):4379-4383.
42. Innocenti M., Zucconi A., Disanza A., Frittoli E., Areces L.B., Steffen A., et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nature Cell Biology 2004, 6(April (4)):319-327.
43. Oda A., Miki H., Wada I., Yamaguchi H., Yamazaki D., Suetsugu S., et al. WAVE/Scars in platelets. Blood 2004, August.
44. Stovold C.F., Millard T.H., Machesky L.M. Inclusion of Scar/WAVE3 in a similar complex to Scar/WAVE1 and 2. BMC Cell Biology 2005, 6(1):11.
45. Yang C., Huang M., DeBiasio J., Pring M., Joyce M., Miki H., et al. Profilin enhances Cdc42-induced nucleation of actin polymerization. Journal of Cell Biology 2000, 150(September (5)):1001-1012.
46. Fukuoka M., Suetsugu S., Miki H., Fukami K., Endo T., Takenawa T. A novel neural Wiskott-Aldrich syndrome protein (N-WASP) binding protein, WISH, induces Arp2/3 complex activation independent of Cdc42. Journal of Cell Biology 2001, 152(February (3)):471-482.
47. Qualmann B., Roos J., DiGregorio P.J., Kelly R.B., Syndapin I. a synaptic dynamin-binding protein that associates with the neural Wiskott-Aldrich syndrome protein. Molecular Biology of the Cell 1999, 10(February (2)):501-513.
48. Ramesh N., Anton I.M., Hartwig J.H., Geha R.S. WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(December (26)):14671-14676.
49. Rivero-Lezcano O.M., Marcilla A., Sameshima J.H., Robbins K.C. Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains. Molecular and Cellular Biology 1995, 15(October (10)):5725-5731.
50. Miki H., Yamaguchi H., Suetsugu S., Takenawa T. IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling. Nature 2000, 408(December (6813)):732-735.
51. Sossey-Alaoui K., Li X., Cowell J.K. c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. Journal of Biological Chemistry 2007, 282(September (36)):26257-26265.
52. Westphal R.S., Soderling S.H., Alto N.M., Langeberg L.K., Scott J.D. Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold. EMBO Journal 2000, 19(September (17)):4589-4600.
53. Suetsugu S., Yamazaki D., Kurisu S., Takenawa T. Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Developmental Cell 2003, 5(October (4)):595-609.
54. Snapper S.B., Rosen F.S., Mizoguchi E., Cohen P., Khan W., Liu C.H., et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998, 9(July (1)):81-91.
55. Lacout C., Haddad E., Sabri S., Svinarchouk F., Garcon L., Capron C., et al. A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood 2003, 102(August (4)):1282-1289.
56. Lebensohn A.M., Kirschner M.W. Activation of the WAVE complex by coincident signals controls actin assembly. Molecular Cell 2009, 36(November (3)):512-524.
57. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Research Part C: Embryo Today 2003, 69(November (4)):272-285.
58. Funa K., Uramoto H. Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. Acta Biochimica Polonica 2003, 50(3):647-658.
59. Sossey-Alaoui K., Li X., Ranalli T.A., Cowell J.K. WAVE3-mediated cell migration and lamellipodia formation are regulated downstream of phosphatidylinositol 3-kinase. Journal of Biological Chemistry 2005, 280(June (23)):21748-21755.
60. Kawamura K., Takano K., Suetsugu S., Kurisu S., Yamazaki D., Miki H., et al. N-WASP and WAVE2 acting downstream of phosphatidylinositol 3-kinase are required for myogenic cell migration induced by hepatocyte growth factor. Journal of Biological Chemistry 2004, 279(December (52)):54862-54871.
61. Oikawa T., Yamaguchi H., Itoh T., Kato M., Ijuin T., Yamazaki D., et al. PtdIns(3,4,5)P3 binding is necessary for WAVE2-induced formation of lamellipodia. Nature Cell Biology 2004, 6(May (5)):420-426.
62. Okkenhaug K., Vanhaesebroeck B. New responsibilities for the PI3K regulatory subunit p85 alpha. Science's STKE 2001, 2001(January (65)):e1.
63. Kapeller R., Chakrabarti R., Cantley L., Fay F., Corvera S. Internalization of activated platelet-derived growth factor receptor-phosphatidylinositol-3' kinase complexes: potential interactions with the microtubule cytoskeleton. Molecular and Cellular Biology 1993, 13(October (10)):6052-6063.
64. Hill K.M., Huang Y., Yip S.C., Yu J., Segall J.E., Backer J.M. N-terminal domains of the class ia phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling. Journal of Biological Chemistry 2001, 276(May (19)):16374-16378.
65. Cory G.O., Garg R., Cramer R., Ridley A.J. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. Wiskott-Aldrich Syndrome protein. Journal of Biological Chemistry 2002, 277(November (47)):45115-45121.
66. Park S.J., Suetsugu S., Takenawa T. Interaction of HSP90 to N-WASP leads to activation and protection from proteasome-dependent degradation. EMBO Journal 2005, 24(April (8)):1557-1570.
67. Suetsugu S., Hattori M., Miki H., Tezuka T., Yamamoto T., Mikoshiba K., et al. Sustained activation of N-WASP through phosphorylation is essential for neurite extension. Developmental Cell 2002, 3(November (5)):645-658.
68. Torres E., Rosen M.K. Contingent phosphorylation/dephosphorylation provides a mechanism of molecular memory in WASP. Molecular Cell 2003, 11(May (5)):1215-1227.
69. Wu X., Suetsugu S., Cooper L.A., Takenawa T., Guan J.L. Focal adhesion kinase regulation of N-WASP subcellular localization and function. Journal of Biological Chemistry 2004, 279(March (10)):9565-9576.
70. Yokoyama N., Lougheed J., Miller W.T. Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase. Journal of Biological Chemistry 2005, 280(December (51)):42219-42226.
71. Miki H., Fukuda M., Nishida E., Takenawa T. Phosphorylation of WAVE downstream of mitogen-activated protein kinase signaling. Journal of Biological Chemistry 1999, 274(September (39)):27605-27609.
72. Kim Y., Sung J.Y., Ceglia I., Lee K.W., Ahn J.H., Halford J.M., et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature 2006, 442(August (7104)):814-817.
73. Leng Y., Zhang J., Badour K., Arpaia E., Freeman S., Cheung P., et al. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(January (4)):1098-1103.
74. Stuart J.R., Gonzalez F.H., Kawai H., Yuan Z.M. c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading. Journal of Biological Chemistry 2006, 281(October (42)):31290-31297.
75. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes and Development 1999, 13(September (18)):2400-2411.
76. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Current Opinion in Cell Biology 1998, 10(October (5)):602-608.
77. Basset P., Okada A., Chenard M.P., Kannan R., Stoll I., Anglard P., et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biology 1997 Mar, 15(8-9):535-541.
78. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. International Journal of Cancer 2002, 99(May (2)):157-166.
79. Vihinen P., Ala-aho R., Kahari V.M. Matrix metalloproteinases as therapeutic targets in cancer. Current Cancer Drug Targets 2005, 5(May (3)):203-220.
80. Sasaki M., Kashima M., Ito T., Watanabe A., Izumiyama N., Sano M., et al. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha. Mediators of Inflammation 2000, 9(3-4):155-160.
81. Reunanen N., Li S.P., Ahonen M., Foschi M., Han J., Kahari V.M. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. Journal of Biological Chemistry 2002, 277(August (35)):32360-32368.
82. Sossey-Alaoui K., Ranalli T.A., Li X., Bakin A.V., Cowell J.K. WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Experimental Cell Research 2005, 308(August (1)):135-145.
83. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Advances in Cancer Research 1998, 74:49-139.
84. Lin A., Minden A., Martinetto H., Claret F.X., Lange-Carter C., Mercurio F., et al. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995, 268(April (5208)):286-290.
85. Minden A., Lin A., Claret F.X., Abo A., Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995, 81(June (7)):1147-1157.
86. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Current Opinion in Cell Biology 1997, 9(April (2)):180-186.
87. Westermarck J., Li S.P., Kallunki T., Han J., Kahari V.M. p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Molecular and Cellular Biology 2001, 21(April (7)):2373-2383.
88. Teng Y., Liu M., Cowell J.K. Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. International Journal of Cancer 2011, 129(December (12)):2825-2835.
89. Berx G., Raspe E., Christofori G., Thiery J.P., Sleeman J.P. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clinical and Experimental Metastasis 2007, 24(8):587-597.
90. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports 2008, 9(June (6)):582-589.
91. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nature Reviews Cancer 2006, 6(April (4)):259-269.
92. Korpal M., Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biology 2008, 5(July (3)):115-119.
93. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry 2008, 283(May (22)):14910-14914.
94. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development 2008, 22(April (7)):894-907.
95. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8(March (6)):843-852.
96. Spaderna S., Brabletz T., Opitz O.G. The miR-200 family: central player for gain and loss of the epithelial phenotype. Gastroenterology 2009, 136(May (5)):1835-1837.
97. Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological and Pharmaceutical Bulletin 2006, 29(May (5)):903-906.
98. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(November (24)):15524-15529.
99. Johnson C.D., Esquela-Kerscher A., Stefani G., Byrom M., Kelnar K., Ovcharenko D., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Research 2007, 67(August (16)):7713-7722.
100. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research 2004, 64(June (11)):3753-3756.
101. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(March (3)):189-198.
102. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435(June (7043)):828-833.
103. Voorhoeve P.M., le S.C., Schrier M., Gillis A.J., Stoop H., Nagel R., et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124(March (6)):1169-1181.
104. Taylor MA, Sossey-Alaoui K, Thompson C, Danielpour D, Schiemann WP. TGF-beta-mediated upregulation of miR-181a promotes breast cancer metastasis by targeting the pro-apoptotic protein Bim. Journal of Clinical Investigation; in press.
105. Sossey-Alaoui K., Safina A., Li X., Vaughan M.M., Hicks D.G., Bakin A.V., et al. Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. American Journal of Pathology 2007, 170(June (6)):2112-2121.
106. Wang W., Goswami S., Lapidus K., Wells A.L., Wyckoff J.B., Sahai E., et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Research 2004, 64(December (23)):8585-8594.
107. Fernando H.S., Sanders A.J., Kynaston H.G., Jiang W.G. WAVE3 is associated with invasiveness in prostate cancer cells. Urologic Oncology 2010, 28(May (3)):320-327.
108. Sossey-Alaoui K., Bialkowska K., Plow E.F. The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. Journal of Biological Chemistry 2009, 284(November (48)):33019-33029.
109. Augoff K., Das M., Bialkowska K., McCue B., Plow E.F., Sossey-Alaoui K. miR-31 is a broad regulator of beta1-integrin expression and function in cancer cells. Molecular Cancer Research 2011, 9(November (11)):1500-1508.
110. Augoff K., McCue B., Plow E.F., Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Molecular Cancer 2012, 11:5.
111. Sossey-Alaoui K., Downs-Kelly E., Das M., Izem L., Tubbs R., Plow E.F. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. International Journal of Cancer 2011, 129(September (6)):1331-1343.
112. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Molecular Cell 2007, 27(July (1)):91-105.
113. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115(December (7)):787-798.
114. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(January (1)):15-20.
115. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szasz A.M., Wang Z.C., et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137(June (6)):1032-1046.
116. Valastyan S., Benaich N., Chang A., Reinhardt F., Weinberg R.A. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes and Development 2009, 23(November (22)):2592-2597.
117. Yamagishi M., Nakano K., Miyake A., Yamochi T., Kagami Y., Tsutsumi A., et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012, 21(January (1)):121-135.
118. Spence H.J., Timpson P., Tang H.R., Insall R.H., Machesky L.M. Scar/WAVE3 contributes to motility and plasticity of lamellipodial dynamics but not invasion in 3D. Biochemical Journal 2012, August.
119. Ghoshal P., Teng Y., Lesoon L.A., Cowell J.K. HIF1A induces expression of the WASF3 metastasis-associated gene under hypoxic conditions. International Journal of Cancer 2012, 131(September (6)):E905-E915.
120. Teng Y., Ngoka L., Mei Y., Lesoon L., Cowell J.K. HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. Journal of Biological Chemistry 2012, 287(March (13)):10051-10059.
121. Teng Y., Ren M.Q., Cheney R., Sharma S., Cowell J.K. Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. British Journal of Cancer 2010, 103(September (7)):1066-1075.
122. Condeelis J., Singer R.H., Segall J.E. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annual Review of Cell and Developmental Biology 2005, 21:695-718.
123. Kulkarni S., Augoff K., Rivera L., McCue B., Khoury T., Groman A., et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS ONE 2012, 7(8):e42895.
124. Kurisu S., Suetsugu S., Yamazaki D., Yamaguchi H., Takenawa T. Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 2005, 24(February (8)):1309-1319.
125. Park S.J., Kim Y.T., Jeon Y.J. Antioxidant dieckol downregulates the Rac1/ROS signaling pathway and inhibits Wiskott-Aldrich syndrome protein (WASP)-family verprolin-homologous protein 2 (WAVE2)-mediated invasive migration of B16 mouse melanoma cells. Molecules and Cells 2012, 33(April (4)):363-369.
126. Safina A., Vandette E., Bakin A.V. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 2007, 26(April (17)):2407-2422.
127. Coso O.A., Chiariello M., Yu J.C., Teramoto H., Crespo P., Xu N., et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995, 81(June (7)):1137-1146.
128. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. Journal of Cell Science 2002, 115(August (Pt 15)):3193-3206.
129. Zhang S., Han J., Sells M.A., Chernoff J., Knaus U.G., Ulevitch R.J., et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. Journal of Biological Chemistry 1995, 270(October (41)):23934-23936.
130. Lambrechts A., Van T.M., Ampe C. The actin cytoskeleton in normal and pathological cell motility. International Journal of Biochemistry and Cell Biology 2004, 36(October (10)):1890-1909.
131. Pollard T.D., Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112(February (4)):453-465.
132. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer 2003, 3(May (5)):362-374.
133. Zhang Y., Guan X.Y., Dong B., Zhao M., Wu J.H., Tian X.Y., et al. Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features. Journal of Cancer Research and Clinical Oncology 2012, July.
134. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60(September (5)):277-300.
135. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(August (6797)):747-752.
136. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(September (19)):10869-10874.
137. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(July (14)):8418-8423.
138. Chiang A.C., Massague J. Molecular basis of metastasis. New England Journal of Medicine 2008, 359(December (26)):2814-2823.
139. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23(October (10)):912-923.
140. Spaderna S., Schmalhofer O., Hlubek F., Jung A., Kirchner T., Brabletz T. Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verhandlungen der Deutschen Gesellschaft fur Pathologie 2007, 91:21-28.
141. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nature Reviews Genetics 2007, 8(May (5)):341-352.
142. Nguyen D.X., Bos P.D., Massague J. Metastasis from dissemination to organ-specific colonization. Nature Reviews Cancer 2009, 9(April (4)):274-284.
143. May C.D., Sphyris N., Evans K.W., Werden S.J., Guo W., Mani S.A. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Research 2011, 13(February (1)):202.
144. Taylor M.A., Parvani J.G., Schiemann W.P. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. Journal of Mammary Gland Biology and Neoplasia 2010, 15(June (2)):169-190.
145. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 2008, 14(June (6)):818-829.
146. Anders C., Carey L.A. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008, 22(October (11)):1233-1239.
147. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer 2009, 9(June (Suppl. 2)):S73-S81.
148. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nature Reviews Clinical Oncology 2010, 7(December (12)):683-692.
149. Finnegan T.J., Carey L.A. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncology 2007, 3(February (1)):55-63.
150. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. The New England Journal of Medicine 2010, 363(November (20)):1938-1948.
151. Jiang Z., Jones R., Liu J.C., Deng T., Robinson T., Chung P.E., et al. RB1 and p53 at the crossroad of EMT and triple negative breast cancer. Cell Cycle 2011, 10(May (10)).
152. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., et al. Triple-negative breast cancer: risk factors to potential targets. Clinical Cancer Research 2008, 14(December (24)):8010-8018.
153. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clinical Cancer Research 2009, 15(April (7)):2302-2310.
154. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127(November (4)):679-695.
155. Padua D., Massague J. Roles of TGFbeta in metastasis. Cell Research 2009, 19(January (1)):89-102.